199 related articles for article (PubMed ID: 37614958)
61. Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.
Fiorillo G; Ibba L; Gargiulo L; Narcisi A; Costanzo A; Valenti M
J Pers Med; 2024 Feb; 14(2):. PubMed ID: 38392619
[TBL] [Abstract][Full Text] [Related]
62. Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Caldarola G; Zangrilli A; Bernardini N; Bavetta M; De Simone C; Graceffa D; Bonifati C; Faleri S; Giordano D; Mariani M; Micheli A; Moretta G; Pagnanelli G; Panasiti V; Provini A; Richetta A; Peris K; Bianchi L
Dermatol Ther; 2022 Jun; 35(6):e15489. PubMed ID: 35385202
[TBL] [Abstract][Full Text] [Related]
63. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting.
Megna M; Potestio L; Camela E; Fabbrocini G; Ruggiero A
Dermatol Ther; 2022 Sep; 35(9):e15667. PubMed ID: 35762107
[TBL] [Abstract][Full Text] [Related]
64. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A; Santos-Alarcón S; Sahuquillo-Torralba A; Rivera-Díaz R; Belinchón-Romero I; Ruiz-Genao D; Romero-Maté A; Ruiz-Villaverde R; Ferran-Farrés M; Gallardo-Hernández F; Almenara-Blasco M; Suarez-Perez JA; González-Cantero Á; Martínez-Lorenzo E; Fernández-Armenteros JM; Del Alcázar-Viladomiu E; García-Latasa J; Rocamora-Durant V; Ara-Martín M; Mateu-Puchades A; Llamas-Velasco M; Vilarrasa E; Velasco-Pastor M; De la Cueva P; Carrascosa JM; Magdaleno-Tapial J
Actas Dermosifiliogr; 2024 Mar; ():. PubMed ID: 38452889
[TBL] [Abstract][Full Text] [Related]
65. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
[TBL] [Abstract][Full Text] [Related]
66. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
Nyholm N; Schnack H; Danø A; Skowron F
Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
[TBL] [Abstract][Full Text] [Related]
67. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
68. Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study.
Megna M; Potestio L; Fabbrocini G; Ruggiero A
Psoriasis (Auckl); 2022; 12():205-212. PubMed ID: 35859710
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
70. Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
McInnes IB; Asahina A; Coates LC; Landewé R; Merola JF; Ritchlin CT; Tanaka Y; Gossec L; Gottlieb AB; Warren RB; Ink B; Assudani D; Bajracharya R; Shende V; Coarse J; Mease PJ
Lancet; 2023 Jan; 401(10370):25-37. PubMed ID: 36493791
[TBL] [Abstract][Full Text] [Related]
71. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
72. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Fargnoli MC; Esposito M; Dapavo P; Parodi A; Rossi M; Tiberio R; Dastoli S; Offidani AM; Argenziano G; Gisondi P; Lo Schiavo A; Loconsole F; Pella P; Bardazzi F; Cusano F; Gattoni M; Nacca M; Cannavò SP; Pellegrini C; Costanzo A;
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):693-700. PubMed ID: 32916767
[TBL] [Abstract][Full Text] [Related]
73. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis.
Bagel J; Tatla D; Hellot S; Knapp B; Murphy C; Peterson L; Sebastian M
J Drugs Dermatol; 2022 Feb; 21(2):162-171. PubMed ID: 35133113
[TBL] [Abstract][Full Text] [Related]
74. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
75. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
76. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
[TBL] [Abstract][Full Text] [Related]
77. Guselkumab shows high efficacy and maintenance in the improvement of response until week 48, a real-life study.
Mastorino L; Siliquini N; Avallone G; Zenone M; Ortoncelli M; Quaglino P; Dapavo P; Ribero S
Dermatol Ther; 2022 Oct; 35(10):e15670. PubMed ID: 35762118
[TBL] [Abstract][Full Text] [Related]
78. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
79. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
80. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Strober B; Tada Y; Mrowietz U; Lebwohl M; Foley P; Langley RG; Warren RB; Wang M; Vanvoorden V; Szilagyi B; Ciaravino V; Paul C
Br J Dermatol; 2023 May; 188(6):749-759. PubMed ID: 36967713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
